EUVIMEDEUVIMED entdecken
Crossref

ADAM17 expression in ACEI/ARB-treated patients with hypertension was comparable to that observed in patients without hypertension

Nora L Falcoff, Gabriela R Guman, Rolando F Seguel, Gabriela C Tabaj iD, Jonathan Honickman, Lucila Daroca, Myriam Nuñez iD, Martin Salazar iD, Gianfranco Parati iD, Mariela M Gironacci iD

American Journal of Hypertension · 01.09.2026 · 39 (9) · 1061-1066

DOI: 10.1093/ajh/hpag040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hypertension, online erschienen am 27.04.2026. Verfasst von Nora L Falcoff und 9 weiteren Autor:innen. Beteiligte Einrichtung: Servicio Unificado de Patología, Hospital Prov de Tórax "Dr. A. Cetrángolo" y Municipal de Vicente López "Prof. B. Houssay", Buenos Aires, Argentina. Hauptthemen laut MEDLINE: ADAM17 Protein, Hypertension, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Type 1 Receptor Blockers. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Universidad de Buenos Aires, CONICET, ANPCYT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ADAM17 (A disintegrin and metalloproteinase 17) contributes to angiotensin-converting enzyme (ACE) 2 shedding in response to angiotensin II–AT1 receptor signaling, potentially shifting the renin–angiotensin system toward its pressor arm. We investigated whether ACE inhibitor (ACEI) or AT1 receptor blocker (ARB) therapy modulates ADAM17 expression.

Methods

ADAM17 protein expression was evaluated by immunohistochemistry in alveolar type II pneumocytes of lung parenchymal samples from untreated control patients (n = 20) and patients treated with ACEI (n = 21) or ARB (n = 17; total ACEI/ARB-treated patients = 38).

Results

There were no significant differences in the proportion of ADAM17-expressing type II pneumocytes between patients without hypertension and ACEI/ARB-treated patients with hypertension (56.1 ± 4.3% vs. 45.8 ± 3.1%, respectively). Similarly, no differences were observed according to smoking status (50.6 ± 4.1% in never smokers, 48.4 ± 4.0% in current smokers, and 50.8 ± 6.8% in former smokers) or sex (49.7 ± 4.2% in women vs. 49.1 ± 3.3% in men). In contrast, a significant age-related decline in the proportion of ADAM17-expressing type II pneumocytes was observed (56.2 ± 3.5% in patients <60 years vs. 43.0 ± 3.5% in patients ≥60 years; P = .005).

Conclusions

These findings suggest that ACEI/ARB therapy, while targeting the pressor axis of the RAS, maintains ADAM17 expression at levels comparable to those in patients without hypertension. ACEI/ARB therapy may represent a potential strategy for the treatment of ADAM17-mediated cardiovascular, pulmonary, and inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAM17 ProteinHypertensionAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersADAM ProteinsHumansFemaleMaleMiddle AgedAgedCase-Control Studies

Stichwörter der Autor:innen

ADAM17angiotensin receptor type 1 blockersangiotensin-converting enzyme 2angiotensin-converting enzyme inhibitors

Substanzen

ADAM17 ProteinADAM17 protein, humanAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersADAM Proteins

Autor:innen und Institutionen

  • Servicio Unificado de Patología, Hospital Prov de Tórax "Dr. A. Cetrángolo" y Municipal de Vicente López "Prof. B. Houssay", Buenos Aires, Argentina.
  • Servicio de Neumonología, Hospital Prov de Tórax "Dr. A. Cetrángolo", Buenos Aires, Argentina.
  • Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Matemática, Buenos Aires, Argentina.
  • Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Hospital Interzonal General Agudos San Martín de La Plata, La Plata, Argentina.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Department of Cardiology, San Luca Hosiptal, IRCCS, Istituto Auxologico Italiano, Milan, Italy.

ORCID-Profile: Gabriela C Tabaj, Myriam Nuñez, Martin Salazar, Gianfranco Parati, Mariela M Gironacci

Förderung

  • Universidad de Buenos Aires
  • CONICET
  • ANPCYT

Zitieren

APA

Falcoff, N. L., Guman, G. R., Seguel, R. F., Tabaj, G. C., Honickman, J., Daroca, L., Nuñez, M., Salazar, M., Parati, G., & Gironacci, M. M. (2026). ADAM17 expression in ACEI/ARB-treated patients with hypertension was comparable to that observed in patients without hypertension. American Journal of Hypertension, 39(9), 1061-1066. https://doi.org/10.1093/ajh/hpag040

Vancouver

Falcoff NL, Guman GR, Seguel RF, Tabaj GC, Honickman J, Daroca L, et al. ADAM17 expression in ACEI/ARB-treated patients with hypertension was comparable to that observed in patients without hypertension. American Journal of Hypertension. 2026;39(9):1061-1066. doi:10.1093/ajh/hpag040

BibTeX
@article{Falcoff2026,
  author = {Falcoff, Nora L and Guman, Gabriela R and Seguel, Rolando F and Tabaj, Gabriela C and Honickman, Jonathan and Daroca, Lucila and Nuñez, Myriam and Salazar, Martin and Parati, Gianfranco and Gironacci, Mariela M},
  title = {ADAM17 expression in ACEI/ARB-treated patients with hypertension was comparable to that observed in patients without hypertension},
  journal = {American Journal of Hypertension},
  year = {2026},
  volume = {39},
  number = {9},
  pages = {1061--1066},
  doi = {10.1093/ajh/hpag040}
}
Kostenlos starten →